75 related articles for article (PubMed ID: 7586196)
1. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure.
Stücker I; Cosme J; Laurent P; Cenée S; Beaune P; Bignon J; Depierre A; Milleron B; Hémon D
Carcinogenesis; 1995 Nov; 16(11):2759-64. PubMed ID: 7586196
[TBL] [Abstract][Full Text] [Related]
2. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
[TBL] [Abstract][Full Text] [Related]
3. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
4. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
[TBL] [Abstract][Full Text] [Related]
5. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
[TBL] [Abstract][Full Text] [Related]
6. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
Dolzan V; Rudolf Z; Breskvar K
Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
[TBL] [Abstract][Full Text] [Related]
7. The effect of tobacco on lung cancer risk depends on CYP2D6 activity.
Bouchardy C; Benhamou S; Dayer P
Cancer Res; 1996 Jan; 56(2):251-3. PubMed ID: 8542575
[TBL] [Abstract][Full Text] [Related]
8. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls.
Tefre T; Daly AK; Armstrong M; Leathart JB; Idle JR; Brøgger A; Børresen AL
Pharmacogenetics; 1994 Apr; 4(2):47-57. PubMed ID: 8081413
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of CYP2D6 and lung cancer risk.
Shaw GL; Falk RT; Frame JN; Weiffenbach B; Nesbitt JC; Pass HI; Caporaso NE; Moir DT; Tucker MA
Cancer Epidemiol Biomarkers Prev; 1998 Mar; 7(3):215-9. PubMed ID: 9521436
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genes and risk of liver cancer.
Agúndez JA; Ledesma MC; Benítez J; Ladero JM; Rodríguez-Lescure A; Díaz-Rubio E; Díaz-Rubio M
Lancet; 1995 Apr; 345(8953):830-1. PubMed ID: 7898230
[TBL] [Abstract][Full Text] [Related]
11. GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp.
Perrett CW; Clayton RN; Pistorello M; Boscaro M; Scanarini M; Bates AS; Buckley N; Jones P; Fryer AA; Gilford J
Carcinogenesis; 1995 Jul; 16(7):1643-5. PubMed ID: 7614700
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
Fujieda M; Yamazaki H; Saito T; Kiyotani K; Gyamfi MA; Sakurai M; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Kamataki T
Carcinogenesis; 2004 Dec; 25(12):2451-8. PubMed ID: 15308589
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers.
Matthias C; Bockmühl U; Jahnke V; Jones PW; Hayes JD; Alldersea J; Gilford J; Bailey L; Bath J; Worrall SF; Hand P; Fryer AA; Strange RC
Pharmacogenetics; 1998 Apr; 8(2):91-100. PubMed ID: 10022746
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquin oxidation genotype and susceptibility to lung cancer.
Agúndez JA; Martínez C; Ladero JM; Ledesma MC; Ramos JM; Martín R; Rodriguez A; Jara C; Benítez J
Clin Pharmacol Ther; 1994 Jan; 55(1):10-4. PubMed ID: 8299311
[TBL] [Abstract][Full Text] [Related]
15. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association.
Caporaso N; DeBaun MR; Rothman N
Pharmacogenetics; 1995; 5 Spec No():S129-34. PubMed ID: 7581482
[TBL] [Abstract][Full Text] [Related]
17. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.
Beyeler C; Armstrong M; Bird HA; Idle JR; Daly AK
Ann Rheum Dis; 1996 Jan; 55(1):66-8. PubMed ID: 8572738
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Vainio H
Environ Health Perspect; 1993 Oct; 101 Suppl 3(Suppl 3):109-12. PubMed ID: 7908263
[TBL] [Abstract][Full Text] [Related]
19. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genotyping and the association with lung cancer susceptibility.
Wolf CR; Smith CA; Bishop T; Forman D; Gough AC; Spurr NK
Pharmacogenetics; 1994 Apr; 4(2):104-6. PubMed ID: 8081411
[No Abstract] [Full Text] [Related]
[Next] [New Search]
